Kornimate/medical-research-clean huggingface dataset:
sun protection of kidney transplant recipients

Conditions: Unspecified Complication of Kidney Transplant; Disorder Related to Renal Transplantation

Summary: this study is being done to evaluate the effectiveness of a sun protection strategies internet-based program for kidney transplant recipients. since the medication taken to preserve the kidney transplant puts kidney transplant recipients at increased risk of developing a sunburn as well a skin cancer, the program will help people learn how to practice effective sun protection for their condition.

cognitive interviews about an internet-based sun protection strategies program will be performed with up to 45 kidney transplant recipients (ktrs) who have participated in past surveys. a second group of 150 ktrs will be asked to evaluate the internet-based module for the effectiveness of information. a third group of 12 ktrs will be asked to evaluate the internet-based module for usability. a fourth group of 160 ktrs will be asked to take part in a randomized controlled trial evaluating the fully developed internet-based sun protection strategies program. kidney transplant recipients (ktrs) are at risk to develop skin cancer. adequate sun protection after transplantation can reduce the risk of developing skin cancer. in 2006, the national kidney foundation (nkf) found that sun protection education delivery and content varied among transplantation centers. clinicians rarely knew when to initiate education about skin cancer risks and prevention including timing and scope, and rarely demonstrated understanding of the importance of reminders for and repeated education of patients. (national kidney foundation 2006) the nkf supported standard, formal, well timed skin cancer prevention information and sending reminders to ktrs at the beginning of summer. aims: 1. to explore culturally sensitive use of terms describing ethnic cultural perceptions of sun burning, pigment darkening after sun exposure and description of skin color by the amount of photoprotective pigment in the skin. 2. to pilot test the internet-based sun protection brochure with english speaking ktrs representing 3 ethnic groups: white, black and hispanic. 3. to explore understanding of the importance of sun protection and the ktrs' confidence in their being able to practice sun protection.

Eligibility criteria:
inclusion criteria: * subjects with a history of kidney transplantation within the last 5 years * speaks english * can see to read * lives in the greater chicago area and can attend a cognitive interview session * 18-85 years old exclusion criteria: * unable to speak english * cognitive impairment or neurologic disease * dementia or insufficient cognitive skills to follow instructions provided at a sixth grade language level * has had a skin cancer

Keywords: kidney transplant renal transplant sun protection skin cancer
six minutes walk test and shuttle walk test in eisenmenger syndrome

Conditions: Eisenmenger Complex; Pulmonary Hypertension; Congenital Heart Defects

Summary: the purpose of this study is to verify the applicability six minutes walk test and shuttle walk test in assessing functional capacity in patients with eisenmenger syndrome. patients will undergo three functional tests, being the six-minute walk test, shuttle walk test and cardiopulmonary exercise test on a cycle ergometer, associated with evaluation of metabolic and ventilatory variables and cardiac monitoring throughout the test.

it has seen an increasing number of individuals with congenital heart diseases mainly due to the development of new diagnostic techniques, assessment and treatment, thereby contributing to longer survival. these individuals that survive to adulthood, many sometimes develop other secondary problems to the underlying pathology, one of pulmonary arterial hypertension. the syndrome eisenmenger is the most advanced form of pulmonary hypertension secondary to congenital heart defects. it is known that patients with pulmonary hypertension secondary congenital heart disease have marked functional limitation and high risk of death. among the various forms of assess exercise capacity, walk test six minutes (6mwt), shuttle walking test and cardiopulmonary exercise test are among the most applicable. little has been studied about the patients with pulmonary hypertension secondary to congenital heart disease and eisenmenger syndrome. the characterization of this profile of patients against the effort becomes necessary and useful in determining strategies and identification of factors that may be limited to functional capacity and quality of life. objectives: to verify the applicability six minutes walk test and shuttle walk test in assessing functional capacity in patients with eisenmenger syndrome. methods: cross-sectional study with patients diagnosed with eisenmenger syndrome, of both sexes, without changing pace or lower limbs, who have performed echocardiography in the last 6 months and clinical stability. patients will undergo three functional tests, being the six-minute walk test, shuttle walk test and cardiopulmonary exercise test on a cycle ergometer, associated with evaluation of metabolic and ventilatory variables and cardiac monitoring throughout the test. also will be held assess respiratory endurance and strength, peripheral muscle strength and manual pinch, heart rate variability, inflammatory mediators and blood lactate, besides questionnaires about quality of life, quality of sleep and daytime drowsiness.

Eligibility criteria:
inclusion criteria: * diagnosis of eisenmenger syndrome * to understand the realization of tests * that do ambulatory monitoring of congenital heart of federal university of são paulo.. exclusion criteria: * donw syndrome * changing pace or lower limbs * neuromuscular disease * pulmonary obstructive disease
nsaids treatment in children with pleuropneumonia

Conditions: Pleuro-pneumonia

Summary: the purpose of this study is to evaluate the influence of routine nsaids treatment for hospitalized children with pleuropneumonia in comparison with acetominophen treatment (all in conjunction with adequate antibiotic therapy).


Eligibility criteria:
inclusion criteria: * age less than 18 years * admission in schneider childrenmc of israel, wards a/c * clinical diagnosis of pneumonia with evidence of pleural effusion on chest x-ray * parental informed consent * follow-up ability after discharge exclusion criteria: * pneumonia secondary to foreign body aspiration * immune deficiency * chronic lung disease other than asthma (cf, cld of prematurity, familial dysautonomia, etc) * significant premorbidity (organ failure, rheumatic disease, etc) * endotracheal/endobronchial devices including tracheostomy. * parental refusal to participate in the study.

Keywords: pleuropneumonia children non steroidal anti inflammatory drugs pleural effusion severe pneumonia
my lifestyle intervention of food and exercise

Conditions: Breast Cancer

Summary: breast cancer risk, and risk of related health problems (e.g., heart disease), is highest among women with a history of breast cancer (stages 1-3) who are also overweight or obese. the purpose of this study is to compare a tailored nutrition, physical activity, and behavioral weight management program for breast cancer survivors against a widely available commercial weight management program. we hypothesize that an intervention tailored to the unique psychological, nutritional and physical needs of breast cancer survivors will provide superior physiological and psychological benefits compared to an existing commercial program.


Eligibility criteria:
inclusion criteria: * female * age 21 to 65 * history of stage 1, 2, or 3 breast cancer * completed primary treatments (chemotherapy, radiation, and/or surgical treatment) for breast cancer (with or without maintenance therapy) within the last 3 months to 5 years of providing consent * be willing/able to attend groups and assessments in gainesville or jacksonville * bmi of 27 to 45 kg/m2 * weight-stable, i.e., not lost/gained ≥ 10 lbs in the preceding 6 months, or since the end of primary treatment exclusion criteria: * history of bariatric surgery * pregnant, lactating, or planning on becoming pregnant in next 12 months. * irritable bowel syndrome * serious infectious disease * chronic malabsorption syndrome * uncontrolled angina within the past 6 months * history of musculo-skeletal or chronic lung diseases that limit physical activity * serum creatinin \> 1.5 mg/dl * uncontrolled or insulin-dependent diabetes (i.e., hemoglobin a1c\ 400 mg/dl; oral medications are not exclusionary) * at-rest blood pressure \> 140/90 mg/hg * myocardial infarction * stroke * congestive heart failure * chronic hepatitis * cirrhosis * chronic pancreatitis * history of solid organ transplantation * cancer treatment within past 5 years (other than for breast cancer) * any other physical condition (other than history of breast cancer) deemed likely to limit 5-year life expectancy or significantly interfere with individuals' ability to participate in a lifestyle intervention involving eating and physical activity changes. * use of antipsychotic medications, monoamine oxidase inhibitors, systemic corticosteroids, human immunodeficiency virus or tuberculosis antibiotics, chemotherapeutics medications, or weight-loss medications. * significant psychiatric disorder * illicit drug use or excessive use of alcohol (i.e., \> 2 drinks/day) * currently participating in weight watcher's or another weight loss program * currently participating in another research study * unable to read english at the 5th grade level * unable/unwilling to provide informed consent * unwilling to receive random assignment to tli or cwlp

Keywords: cancer breast cancer breast cancer prevention breast cancer recurrence weight loss weight management overweight obesity
prevalence of diabetic retinopathy in type 2 diabetic patients

Conditions: Diabetic Retinopathy

Summary: to determine the stage of diabetic retinopathy (dr) and the presenting symptoms at the time of ophthalmological examination of diabetic individuals .

diabetic retinopathy (dr) is the main cause of decreased vision and blindness in patients with diabetes throughout the world . in egypt, the estimated prevalence of diabetes mellitus (dm) is expected to rise from 5-10% in the 1990s to\>13% of the population over 20 years old by 2025 . the estimation of the prevalence of diabetic retinopathy (dr) is challenging due to the great variation in the study populations, methodologies, and grading schemes . globally, the prevalence of dr and diabetic macular edema (dmo) is expected to rise from the estimates for the period 2015-2019 (27%) due to the expected increase in the life expectancy of people living with dm . diabetic retinopathy is now the 5th leading cause of blindness worldwide and is the main cause of blindness in working population . blindness due to diabetic retinopathy is more common in type 1 diabetics (4%) than in type 2 (1.6%) . the exact mechanism of how prolonged hyperglycaemia causes retinopathy is still unclear, however studies have shown that prolonged hyperglycaemia alters retinal perfusion thereby disturbing the normal physiological and homeostatic state of the retina, in turn causing retinopathy . fortunately, much of the visual loss from dr is preventable, and the rates of vision loss from diabetes and dr have steadily declined over the past few decades. such improvements in visual outcomes for dr are multifactorial, and are due in large part to a combination of better systemic risk factor control, coupled with advances in ocular disease assessment, screening, imaging and treatment in recent years .

Eligibility criteria:
inclusion criteria: * all known diabetic patients ( type 2 ) or patients who were later on diagnosed with type 2 diabetes mellitus as per american diabetes association (ada) criteria who presented for the first time to assuit university hospital opthalomolgy outpatient clinics during study duration (one year) will be included in the study . diabetic retinopathy will be classified according to early treatment diabetic retinopathy study (etdrs) classification as mild, moderate, severe and very severe non proliferative diabetic retinopathy (npdr) and proliferative diabetic retinopathy (pdr). patients with vitreous hemorrhage, rubeosis iridis, neovascular glaucoma or tractional retinal detachment will be classified as having advanced diabetic eye disease (aded). exclusion criteria: * type 1 diabetic patients or patients with diabetes below 25 years old will be excluded from the study .
to assess the level of adherence of subjects receiving saizen® via easypod™ in hungary

Conditions: Growth Disorders

Summary: this is a hungarian, multicentre, observational study to study adherence and long term outcomes of therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment to assess the level of adherence of subject receiving saizen® via easypod™.

subjects will be enrolled in a multicenter longitudinal observational study. parents/subjects will provide their informed consent/assent to upload their data for population-based analyses and, ultimately, clinical outcomes. adherence data will be primarily derived from the easypod™ device combined with physician data entry of outcome measures. data will be collected retrospectively and prospectively. this will allow the establishment of adherence profiles and subsequent clinical outcomes. collected data will be also analyzed in a multinational pooled analysis of comparable national studies. primary objective: • to assess the level of adherence of subjects receiving saizen® via easypod™. secondary objective: * to identify adherence subject profiling * to describe the impact of adherence on clinical outcomes for subject receiving saizen® via easypod™ * to asses the impact of adherence on insulin-like growth factor-1 (igf-1) (i.e. above, below or within normal ranges)

Eligibility criteria:
inclusion criteria: * administered growth hormone via the easypod™ electromechanical device according to the summary of product characteristics (smpc) * over the age of \>2 years * under \<18 years of age, or over 18 without fusion of growth plates * parent's or guardian's written informed consent, given before entering data into the observational study, with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. exclusion criteria: * subjects taking growth hormone in whom growth plates have fused (i.e. for taking growth hormone for it's metabolic effects) * contra-indications to saizen® as defined in the smpc * use of an investigational drug or participation in an interventional clinical study

Keywords: growth disorders saizen easypod growth hormone pediatric subject
cardiovascular protective role of laser acupuncture in systemic lupus

Conditions: System; Lupus Erythematosus

Summary: systemic lupus erythematosus is a chronic and multisystemic autoimmune disorder which predominantly affecting women. the most common cause of death in lupus patients affected by disease for more than 5 years is cardiovascular disease due to presence of some factors as oxidative stress, pro-inflammatory cytokines , dyslipidemia, diabetes, and hypertension.

laser acupuncture (active or sham) for one month (3 days/week ) on acupoint number 14 of gv meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser will be applied for 1 min on every acupiont) in lupus females

Eligibility criteria:
inclusion criteria: * lupus females * 60 patients exclusion criteria: * pregnancy * cardiovascular diseases * respiratory diseases
determination of optimum duration of treatment with bromfenac (xibrom) eyedrops following cataract surgery

Conditions: Cataracts

Summary: the objective of this study is to determine if an extension of bromfenac bid monotherapy is effective in the decreasing retinal thickening post cataract iol placement surgery. no studies exist on how long to treat with an nsaid post cataract iol placement surgery. currently, nsaid therapy post iol placement surgery is in conjunction with steroid treatment, lasting approximately 3 weeks. this study is designed to examine if there is benefit to extending nsaid monotherapy in regards to macular thickening and the incidence of cme.


Eligibility criteria:
inclusion criteria: * male or female \>18 years of age scheduled to undergo bilateral cataract surgery * patients with systemic diseases will be enrolled only if there are no ocular manifestations of their disease (e.g. diabetics with normal retinal exams) * expected visual outcome of bcva \> \[greater than or equal to\] 20/30 postoperatively * ability to provide informed consent, take study medications as directed, and likely to complete all study visits exclusion criteria: * known contraindication to any study medication or any of their components * required use of ocular medications other than the study medications during the study * significant amd, epi-retinal membrane, retinal vein occlusion, diabetic macular edema, or any macular disease predisposing them to cystoid macular edema. * posterior capsule rupture, vitreous loss during surgery or any other complication that in the surgeon's opinion, could reduce potential for targeted visual outcome * anticipated need for mechanical iris dilating devices
positron emission tomography/computed tomography (pet/ct) imaging for radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and tolerability and diagnostic performance of bay86-4367 in patients with prostate cancer and healthy volunteers

Conditions: Diagnostic Imaging

Summary: visual assessment of diagnostic pet/ct (positron emission tomography/computed tomography) images obtained after a single intravenous injection of bay86-4367 in patients with cancer


Eligibility criteria:
inclusion criteria: * healthy volunteers: * males, \>/=50 and \<= 65 years of age * cancer patients: * males \>/= 45 years of age * patients with recurrent prostate cancer had a positive choline pet/ct for detection, or staging, or restaging of cancer, evaluation of the primary prostate cancer detection rate with bay 86-4367 in comparison to histology as standard of truth (choline pet/ct is optional). exclusion criteria: * exclusion criteria for all healthy volunteers and patients: * concurrent severe and/or uncontrolled and/or unstable other medical disease (e.g. poorly controlled diabetes, congestive heart failure, myocardial infarction within 12 months prior to planned injection of bay 86-4367, unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe pulmonary disease) which could compromise participation in the study * known sensitivity to the study drug or components of the preparation.

Keywords: neoplasm pet/ct diagnosis pet tracer
the change cycle intervention for improving quality of life in breast cancer survivors

Conditions: Breast Cancer

Summary: this study is proposed to assess long-term quality of life issues in breast cancer survivors by measuring the impact on the quality of life made by the structured "change cycle work shop" coping class as compared to current local standard of care programs. it has been shown that breast cancer treatment can have long-term bio-psychosocial consequences. specific evidence-based interventions are needed to address quality of life concerns in order to improve the overall outcome of breast cancer and its treatment beyond the focus on mortality rate.

breast cancer is the most common cancer among north american women. a combination of screening mammography and improvements in treatment has resulted in a substantial decrease in mortality which explains why more women diagnosed at a younger age are becoming long-term survivors.consequently, quality of life (ql) issues have become increasingly important in the contemporary multidisciplinary management of breast cancer. standard of car survivorship program has evolved over several years to include 3 facets: (1)clinical surveillance program to include routine follow up exams; (2) local support group programs; and (3) rehabilitation program offering physical and occupational rehab, along with lymphedema prevention and treatment. many studies have reported on successful interventions (listed in our references) with improvements in quality of life; however the effects did not last long after intervention. this has brought into question the real value of such interventions. the proposed class will focus on teaching life skills that have shown long-lasting effect in the corporate world of change. thus, our goal is to determine if the impact of the class will be similar in the healthcare arena, specifically cancer survivorship. our last study on assessing quality of life revealed that patients were suffering deficits in quality of life, specifically with regard to the emotional scale despite the standard of care approach available. we therefore propose this intervention to be studied as proof of concept so that depending on the results of the proposed trial, this class can become a routine part of the survivorship program.

Eligibility criteria:
inclusion criteria: * female * 18 years old or older * established diagnosis of breast cancer * diagnosis from january 2010 onward * must be patient of texas tech university health sciences center-breast center of excellence * must agree to participate in study structure of randomization exclusion criteria: * those who do not accept randomization * women with medical conditions that preclude them from attending the coping class * women with personal issues that preclude them from attending the coping class

Keywords: breast cancer survivorship coping quality of life